Pasatru-treated adults had no new abnormal bone growth at week 84; the placebo group had 9 lesions.
Regeneron Pharmaceuticals (NASDAQ: REGN) reported 84-week results from the Phase 3 OPTIMA trial of Pasatru, showing sustained efficacy in halting new bone growth and reducing flare-ups in adults with FOP. Pasatru is FDA-approved for this use. The trial involved 63 patients, with 58 completing the extension phase. Pasatru demonstrated a well-tolerated safety profile. Regeneron plans a Phase 3 trial in adolescents and children with FOP.
How this was made
The 30-second read
Why it matters
The company reports sustained efficacy and consistent safety from weeks 56 to 84 from the OPTIMA Phase 3 trial, presented as late-breaking data at ASBMR.
Market read
Week 84 durability data versus placebo supports confidence in long-term disease control, which can influence valuation and sentiment for Regeneron’s rare-disease franchise.
What to watch
The excerpt omits key efficacy numbers at week 84 beyond the placebo lesion count, and it does not specify whether regulators will require additional analyses for label expansion.
Background
Pasatru (garetosmab-grts) is FDA-approved for adults with FOP to reduce new heterotopic ossification lesions and clinician-assessed flare-ups, based on a 56-week placebo-controlled trial.
Ticker impact
Regeneron announced positive 84-week Phase 3 OPTIMA results for Pasatru, showing no new abnormal bone growth at week 84 versus placebo lesions.
Likely upward bias as investors price in stronger long-term efficacy durability and lower uncertainty around label expansion and uptake.
The article reports late-breaking, longer-term trial data (weeks 56 to 84) and reiterates FDA approval context, which can influence expectations for ongoing development and market confidence, though it is not a new FDA decision.
Market effects
Reinforces the rare-disease biotech narrative around Activin A pathway targeting and durability of disease-modifying effects.
Primarily US biotech sentiment, with potential spillover to rare-disease peers focused on musculoskeletal/orthopedic indications.
Supports global regulatory review momentum since the EU submission is described as under review.
Counterpoint
Longer-term extension data may not change near-term revenue expectations if the product is already FDA-approved; investors may demand additional endpoints, safety quantification, or regulatory milestones.
Key entities
- companyRegeneron Pharmaceuticals, Inc.
Sponsor of the OPTIMA Phase 3 trial and developer of Pasatru.
- drugPasatru (garetosmab-grts)
VelocImmune-derived fully human monoclonal antibody targeting Activin A signaling in FOP.
- clinical_trialOPTIMA trial
Phase 3, randomized, double-blind, placebo-controlled study with an extension to at least 84 weeks.
- conferenceASBMR Annual Meeting
Venue where late-breaking oral data for weeks 56 to 84 were presented.
